🔎 Trials Near Me

Akèy › Sklerodèm › Kalifòni › Los Angeles

Etid klinik pou Sklerodèm nan Los Angeles, CA

7 etid pou Sklerodèm ap chèche patisipan nan sit nan ak bò kote Los Angeles (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

Ap rekriteFaz 3
  • University of California Los Angeles, Los Angeles
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07497087

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

Ap rekriteFaz 2
  • UCLA Ronald Reagan University of California Los Angeles Medical Center, Los Angeles
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06655155

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Ap rekriteFaz 2/3
  • GSK Investigational Site, Los Angeles
  • GSK Investigational Site, Los Angeles
  • GSK Investigational Site, Los Angeles
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT05878717

Platform Clinical Study for Conquering Scleroderma

Ap rekriteFaz 2
  • Keck School of Medicine at USC Medical Center, Los Angeles
  • Cedars-Sinai Medical Center, Los Angeles
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT06195072

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

Ap rekriteFaz 2
  • Artiva Investigational Site Los Angeles, Los Angeles
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT06991114

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Ap rekriteFaz 1
  • Children's Hospital Los Angeles Division Of Rheumatology, Los Angeles
Laj 12 a 70 · Tout sèks · Mizajou May 22, 2026 · NCT06308978

Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

Ap rekriteFaz 2
  • aTyr Investigative Site, Los Angeles
Laj 18 ak plis · Tout sèks · Mizajou May 7, 2025 · NCT05892614

Etid Sklerodèm nan lòt vil

Lòt etid nan Los Angeles

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.